BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

CV Therapeutics, Inc. 

3172 Porter Drive

Palo Alto  California  94304  U.S.A.
Phone: 650-384-8500 Fax: 650-858-0390


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

Genta Incorporated 





 Company News
Gilead Sciences, Inc. (GILD) Successfully Completes Tender Offer for Shares of CV Therapeutics, Inc. (CVTX) With Over 88 Percent of Shares Tendered 4/15/2009 9:15:12 AM
CV Therapeutics, Inc. (CVTX)'s Board of Directors Recommends Stockholders Accept Gilead Sciences Ltd. (GILD)'s $20.00 per Share Cash Tender Offer 3/19/2009 11:06:37 AM
CV Therapeutics, Inc. (CVTX) Announces Presentations at the American College of Cardiology 58th Annual Scientific Session 3/17/2009 12:50:27 PM
Astellas Pharma Inc. (JOBS) Pulls Plug on $1 Billion CV Therapeutics, Inc. (CVTX) (JOBS) Bid 3/16/2009 7:33:14 AM
CV Therapeutics, Inc. (CVTX)'s (JOBS) Board of Directors Rejects Astellas Pharma Inc.'s (JOBS) Tender Offer 3/13/2009 7:30:50 AM
Gilead Sciences, Inc. (GILD) Buying CV Therapeutics, Inc. (CVTX) for $1.4 Billion 3/12/2009 7:25:47 AM
Astellas Pharma US, Inc. to Nominate Two Directors and Submit Proposal to Remove Remaining Four Directors of CV Therapeutics, Inc. (CVTX) 3/6/2009 8:43:23 AM
CV Therapeutics, Inc. (CVTX) Reports Phase 1 Data Showing Proof of Concept for CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3/5/2009 11:01:21 AM
CV Therapeutics, Inc. (CVTX)'s Ranexa(R) Now Available in United Kingdom and Germany 3/3/2009 11:41:14 AM
CV Therapeutics, Inc. (CVTX) Advises Stockholders to Take No Action at This Time in Response to Astellas Pharma Inc.' Tender Offer 3/2/2009 8:59:43 AM
12345678910...